Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).

Article  PubMed  Google Scholar 

Ma, B., Wells, A., Wei, L. & Zheng, J. Prostate cancer liver metastasis: dormancy and resistance to therapy. Semin. Cancer Biol. 71, 2–9 (2021).

Article  CAS  PubMed  Google Scholar 

Tsilimigras, D. I. et al. Liver metastases. Nat. Rev. Dis. Prim. 7, 27 (2021).

Article  PubMed  Google Scholar 

Gandaglia, G. et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur. Urol. 68, 325–334 (2015).

Article  PubMed  Google Scholar 

Pond, G. R. et al. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur. Urol. 65, 3–6 (2014).

Article  PubMed  Google Scholar 

Halabi, S. et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J. Clin. Oncol. 34, 1652–1659 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heck, M. M. et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur. Urol. 75, 920–926 (2019).

Article  CAS  PubMed  Google Scholar 

Rahbar, K. et al. PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur. J. Nucl. Med. Mol. Imaging 45, 12–19 (2018).

Article  CAS  PubMed  Google Scholar 

Beltran, H. et al. A phase II trial of the Aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin. Cancer Res. 25, 43–51 (2019).

Article  CAS  PubMed  Google Scholar 

Gandaglia, G. et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74, 210–216 (2014).

Article  PubMed  Google Scholar 

Haffner, M. C. et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123, 4918–4922 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Dessel, L. F. et al. Application of circulating tumor DNA in prospective clinical oncology trials — standardization of preanalytical conditions. Mol. Oncol. 11, 295–304 (2017).

Article  PubMed  PubMed Central  Google Scholar 

von Eyben, F. E., Picchio, M., von Eyben, R., Rhee, H. & Bauman, G. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur. Urol. Focus. 4, 686–693 (2018).

Article  PubMed  Google Scholar 

Damjanovic, J. et al. 68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer. Cancer Imaging 19, 37 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Roviello, G., Petrioli, R., Villari, D. & D’Angelo, A. Treating de novo metastatic castration-sensitive prostate cancer with visceral metastases: an evolving issue. Clin. Genitourin. Cancer 19, 83–86 (2021).

Article  PubMed  Google Scholar 

Khreish, F. et al. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy. Eur. J. Nucl. Med. Mol. Imaging 48, 103–112 (2021).

Article  CAS  PubMed  Google Scholar 

Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578–583 (2000).

Article  CAS  PubMed  Google Scholar 

Shah, R. B. et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 64, 9209–9216 (2004).

Article  CAS  PubMed  Google Scholar 

Pezaro, C. et al. Visceral disease in castration-resistant prostate cancer. Eur. Urol. 65, 270–273 (2014).

Article  CAS  PubMed  Google Scholar 

van den Bergh, G. P. A. et al. Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry. Prostate Cancer Prostatic Dis. 26, 162–169 (2023).

Article  PubMed  Google Scholar 

Deng, Y. et al. A surveillance, epidemiology and end results database analysis of the prognostic value of organ-specific metastases in patients with advanced prostatic adenocarcinoma. Oncol. Lett. 18, 1057–1070 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Shou, J., Zhang, Q., Wang, S. & Zhang, D. The prognosis of different distant metastases pattern in prostate cancer: a population based retrospective study. Prostate 78, 491–497 (2018).

Article  CAS  PubMed  Google Scholar 

Cotogno, P. M., Ranasinghe, L. K., Ledet, E. M., Lewis, B. E. & Sartor, O. Laboratory-based biomarkers and liver metastases in metastatic castration-resistant prostate cancer. Oncologist 23, 791–797 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ranasinghe, L. et al. Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer. Cancer Treat. Res. Commun. 20, 100151 (2019).

Article  PubMed  Google Scholar 

Rahbar, K. et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J. Nucl. Med. 58, 85–90 (2017).

Article  CAS  PubMed  Google Scholar 

Ahmadzadehfar, H. et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur. J. Nucl. Med. Mol. Imaging 48, 113–122 (2021).

Article  CAS  PubMed  Google Scholar 

Kessel, K. et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617. Theranostics 9, 4841–4848 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luna-Gutierrez, M. et al. Improving overall survival and quality of life in patients with prostate cancer and neuroendocrine tumors using 177Lu-iPSMA and 177Lu-DOTATOC: experience after 905 treatment doses. Pharmaceutics 15, 1988 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fendler, W. P. et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin. Cancer Res. 25, 7448–7454 (2019).

Article  CAS  PubMed  Google Scholar 

Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208–1216 (2020).

Article  CAS  PubMed  Google Scholar 

Maitland, N. J. Resistance to antiandrogens in prostate cancer: is it inevitable, intrinsic or induced? Cancers 13, 327 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buxton, A. K., Abbasova, S., Bevan, C. L. & Leach, D. A. Liver microenvironment response to prostate cancer metastasis and hormonal therapy. Cancers 14, 6189 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berry, W. R., Laszlo, J., Cox, E., Walker, A. & Paulson, D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44, 763–775 (1979).

Article  CAS  PubMed  Google Scholar 

Factors in the prognosis of carcinoma of the prostate: a cooperative study. The Veterans Administration Cooperative Urological Research Group. J. Urol. 100, 59–65 (1968).

Google Scholar 

Petrylak, D. P., Scher, H. I., Li, Z., Myers, C. E. & Geller, N. L. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70, 2870–2878 (1992).

Article  CAS  PubMed  Google Scholar 

Chi, K. N. et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann. Oncol. 27, 454–460 (2016).

Article  CAS  PubMed  Google Scholar 

Conteduca, V. et al. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncol. 11, 2881–2891 (2015).

Article  CAS  PubMed